Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,691 | 282 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $967.76 | 43 | $0 (2024) |
| Biogen, Inc. | $570.81 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $428.03 | 25 | $0 (2024) |
| Genentech USA, Inc. | $319.70 | 17 | $0 (2023) |
| PFIZER INC. | $243.66 | 11 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $237.58 | 11 | $0 (2024) |
| Amgen Inc. | $209.52 | 8 | $0 (2022) |
| UCB, Inc. | $185.07 | 7 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $181.13 | 7 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $171.95 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,048 | 42 | ABBVIE INC. ($252.51) |
| 2023 | $1,217 | 51 | ABBVIE INC. ($325.58) |
| 2022 | $1,098 | 59 | Novartis Pharmaceuticals Corporation ($203.14) |
| 2021 | $705.23 | 33 | AbbVie Inc. ($172.19) |
| 2020 | $451.88 | 22 | Upsher-Smith Laboratories LLC ($77.91) |
| 2019 | $175.53 | 9 | Genentech USA, Inc. ($45.04) |
| 2018 | $382.93 | 23 | Biogen, Inc. ($133.33) |
| 2017 | $611.82 | 43 | Biogen, Inc. ($141.12) |
All Payment Transactions
282 individual payment records from CMS Open Payments — Page 10 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2018 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: NEUROLOGY | ||||||
| 06/05/2018 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: NEUROLOGY | ||||||
| 05/31/2018 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $10.67 | General |
| Category: NEUROLOGY | ||||||
| 05/29/2018 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: NEUROLOGY | ||||||
| 05/25/2018 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: CNS | ||||||
| 05/03/2018 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | In-kind items and services | $11.24 | General |
| Category: NEUROLOGY | ||||||
| 04/10/2018 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: NEUROLOGY | ||||||
| 03/31/2018 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $9.48 | General |
| Category: NEUROLOGY | ||||||
| 03/20/2018 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: NEUROLOGY | ||||||
| 03/16/2018 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: NEUROLOGY | ||||||
| 03/07/2018 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Food and Beverage | In-kind items and services | $9.35 | General |
| Category: NEUROLOGY | ||||||
| 02/22/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Central Nervous System | ||||||
| 01/19/2018 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA, ZINBRYTA | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: NEUROLOGY | ||||||
| 01/10/2018 | EMD Serono, Inc. | Rebif (Biological) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Neurology | ||||||
| 12/18/2017 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $15.07 | General |
| 12/11/2017 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | In-kind items and services | $10.01 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2017 | Novartis Pharmaceuticals Corporation | AIMOVIG (Biological) | Food and Beverage | In-kind items and services | $10.57 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2017 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Immunology | ||||||
| 11/13/2017 | Teva Pharmaceuticals USA, Inc. | SD809-HD (Drug) | Food and Beverage | In-kind items and services | $10.95 | General |
| Category: Central Nervous System | ||||||
| 11/07/2017 | EMD Serono, Inc. | Rebif (Biological) | Food and Beverage | Cash or cash equivalent | $19.84 | General |
| Category: Neurology | ||||||
| 11/03/2017 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: NEUROLOGY | ||||||
| 11/02/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 10/30/2017 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: Immunology | ||||||
| 10/24/2017 | EMD Serono, Inc. | Rebif (Biological) | Food and Beverage | Cash or cash equivalent | $16.73 | General |
| Category: Neurology | ||||||
| 10/16/2017 | PFIZER INC. | LYRICA (Drug) | Food and Beverage | In-kind items and services | $10.34 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 578 | 774 | $200,038 | $70,913 |
| 2022 | 11 | 570 | 780 | $180,777 | $67,622 |
| 2021 | 10 | 525 | 749 | $175,794 | $66,147 |
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 100 | 172 | $38,917 | $16,732 | 43.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 123 | 124 | $54,553 | $15,632 | 28.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 88 | 151 | $23,855 | $9,845 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 72 | $17,280 | $6,771 | 39.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 36 | 38 | $23,619 | $6,653 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 63 | $10,268 | $4,397 | 42.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 60 | 64 | $7,981 | $2,998 | 37.6% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2023 | 22 | 22 | $8,522 | $2,548 | 29.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 15 | 27 | $5,692 | $2,374 | 41.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $7,270 | $2,111 | 29.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 21 | $2,082 | $851.32 | 40.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 109 | 109 | $47,953 | $17,158 | 35.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 120 | 183 | $41,406 | $15,772 | 38.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 128 | 219 | $34,598 | $13,003 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 43 | $10,320 | $4,279 | 41.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 51 | $8,312 | $3,466 | 41.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 18 | 37 | $7,800 | $3,431 | 44.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 27 | $7,993 | $2,897 | 36.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 46 | 56 | $6,653 | $2,627 | 39.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $6,543 | $2,085 | 31.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 11 | 11 | $6,621 | $1,774 | 26.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 22 | 26 | $2,578 | $1,130 | 43.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 130 | 258 | $40,759 | $15,890 | 39.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 95 | 95 | $41,794 | $14,597 | 34.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 93 | 127 | $28,735 | $11,155 | 38.8% |
About Dr. Mahsa Matloobi, M.D
Dr. Mahsa Matloobi, M.D is a Neurology healthcare provider based in Long Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/15/2009. The National Provider Identifier (NPI) number assigned to this provider is 1609101211.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mahsa Matloobi, M.D has received a total of $5,691 in payments from pharmaceutical and medical device companies, with $1,048 received in 2024. These payments were reported across 282 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($5,691).
As a Medicare-enrolled provider, Matloobi has provided services to 1,673 Medicare beneficiaries, totaling 2,303 services with total Medicare billing of $204,682. Data is available for 3 years (2021–2023), covering 32 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Long Beach, CA
- Active Since 10/15/2009
- Last Updated 04/30/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1609101211
Products in Payments
- TYSABRI (Biological) $430.98
- NURTEC ODT (Drug) $405.02
- BOTOX (Biological) $392.07
- KESIMPTA (Drug) $367.36
- UBRELVY (Drug) $350.24
- OCREVUS (Biological) $299.82
- QULIPTA (Drug) $203.56
- Aimovig (Biological) $194.45
- NUPLAZID (Drug) $171.95
- INGREZZA (Drug) $163.04
- Rebif (Biological) $147.91
- APTIOM (Drug) $133.61
- ULTOMIRIS (Biological) $127.62
- TECFIDERA (Drug) $122.55
- VYVGART (Drug) $80.40
- TOSYMRA SUMATRIPTAN NASAL SPRAY (Drug) $77.91
- AUBAGIO (Drug) $75.63
- AMYVID (Drug) $71.63
- SOLIRIS (Biological) $71.54
- DUOPA (Drug) $65.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Long Beach
Randolph Shey, M.d, M.D
Neurology — Payments: $28,759
Ignacio Carrillo-Nunez, M.d, M.D
Neurology — Payments: $17,849
Thanh Le, M.d, M.D
Neurology — Payments: $12,430
George Wang, M.d, M.D
Neurology — Payments: $10,988
Mary Dyes, M.d, M.D
Neurology — Payments: $7,453
Dr. Elina Melamed, Md, MD
Neurology — Payments: $1,400